CA
NZ
UK
AU
IND
US
…
iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days; Zio XT System, a prescription-only remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and Zio ECG Utilization Software System, which supports the capture and analysis of ECG data. In addition, the company offers Zio AT System, a prescription-only remote ECG monitoring system, which consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days, as well as incorporates the Zio AT wireless gateway to provide connectivity between the patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with BioIS to develop and commercialize pulse oximetry, accelerometry, and trending non-invasive blood pressure technologies for use within ambulatory cardiac monitoring products and services. The company was formerly known as iRhythm Technologies, Inc. and changed its name to iRhythm Holdings, Inc. in January 2026. iRhythm Holdings, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
iRhythm Technologies provides ambulatory cardiac monitoring through its Zio wearable patch and proprietary AI analytics that deliver physician-ready arrhythmia reports. Long-term growth may be supported by rising atrial fibrillation screening, broader clinical adoption and recurring service revenue from its data-driven platform. Investors may find the company attractive because the device-plus-software model and proprietary rhythm dataset appear positioned to drive scalable margins.
Principal risks include dependence on a single core monitoring product, reimbursement and regulatory uncertainty, competitive pressure from alternative monitoring technologies, and execution risk as the company scales.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -43.60M | -112.72M | -122.66M | -115.89M | -100.99M |
| Net income | -44.55M | -113.29M | -123.41M | -116.16M | -101.36M |
| Selling general administrative | 492.55M | 418.56M | 385.64M | 322.20M | 274.84M |
| Gross profit | 527.25M | 407.53M | 331.81M | 281.63M | 213.57M |
| Reconciled depreciation | 26.48M | 25.78M | 22.14M | 19.61M | 9.84M |
| Ebit | -30.44M | -99.90M | -119.01M | -87.18M | -99.94M |
| Ebitda | -3.96M | -74.13M | -96.86M | -85.14M | -99.83M |
| Depreciation and amortization | 26.48M | 25.78M | 22.14M | 2.04M | 0.12M |
| Non operating income net other | - | - | - | 2.04M | - |
| Operating income | -36.81M | -115.50M | -125.16M | -87.18M | -99.94M |
| Other operating expenses | 783.95M | 707.34M | 617.84M | 498.10M | 422.77M |
| Interest expense | 13.15M | 12.82M | 3.65M | 4.14M | 1.17M |
| Tax provision | 0.95M | 0.56M | 0.75M | 0.27M | 0.37M |
| Interest income | 21.52M | 21.94M | 6.16M | - | - |
| Net interest income | 8.37M | 9.12M | 2.50M | -4.14M | -1.17M |
| Non recurring | - | - | - | 26.61M | - |
| Income tax expense | 0.95M | 0.56M | 0.75M | 0.27M | 0.37M |
| Total revenue | 747.14M | 591.84M | 492.68M | 410.92M | 322.82M |
| Total operating expenses | 564.06M | 523.04M | 456.97M | 368.81M | 313.51M |
| Cost of revenue | 219.89M | 184.31M | 160.88M | 129.29M | 109.26M |
| Total other income expense net | -6.79M | 2.78M | 2.50M | -28.71M | -1.05M |
| Net income from continuing ops | -44.55M | -113.29M | -123.41M | -116.16M | -101.36M |
| Net income applicable to common shares | - | - | - | -116.16M | -101.36M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 1020.04M | 931.45M | 433.14M | 448.22M | 462.97M |
| Other current assets | 21.66M | 16.29M | 21.59M | 10.55M | 9.69M |
| Total liab | 867.30M | 840.54M | 223.05M | 208.41M | 183.45M |
| Total stockholder equity | 152.75M | 90.91M | 210.10M | 239.81M | 279.51M |
| Other current liab | 128.75M | 80.89M | 83.36M | 65.50M | 51.49M |
| Common stock | 0.03M | 0.03M | 0.03M | 0.03M | 0.03M |
| Capital stock | 0.03M | 0.03M | 0.03M | 0.03M | 0.03M |
| Retained earnings | -803.45M | -758.89M | -645.61M | -522.20M | -406.05M |
| Other liab | - | - | - | 1.31M | 0.70M |
| Good will | 0.86M | 0.86M | 0.86M | 0.86M | 0.86M |
| Other assets | - | - | - | 22.25M | 16.05M |
| Cash | 236.01M | 419.60M | 36.17M | 78.83M | 127.56M |
| Total current liabilities | 151.89M | 110.92M | 107.37M | 89.10M | 87.85M |
| Current deferred revenue | 4.20M | 2.93M | 3.31M | 3.05M | 3.05M |
| Net debt | 495.17M | 317.31M | 93.65M | 52.21M | -9.85M |
| Short term debt | 16.69M | 15.87M | 15.16M | 13.03M | 22.81M |
| Short long term debt | - | - | - | - | 11.67M |
| Short long term debt total | 731.18M | 736.91M | 129.82M | 131.04M | 117.71M |
| Other stockholder equity | 955.76M | 849.61M | 855.78M | 762.38M | 685.59M |
| Property plant equipment | - | - | - | 75.67M | 140.53M |
| Total current assets | 702.76M | 645.82M | 230.81M | 288.77M | 305.52M |
| Long term investments | 69.91M | 61.90M | - | - | - |
| Net tangible assets | - | - | - | 238.95M | 278.65M |
| Short term investments | 347.75M | 115.96M | 97.59M | 134.31M | 111.57M |
| Net receivables | 75.71M | 79.94M | 61.48M | 49.92M | 46.43M |
| Long term debt | 649.50M | 646.44M | 34.95M | 34.94M | 9.69M |
| Inventory | 21.63M | 14.04M | 13.97M | 15.15M | 10.27M |
| Accounts payable | 2.26M | 7.22M | 5.54M | 7.52M | 10.51M |
| Accumulated other comprehensive income | 0.40M | 0.17M | -0.11M | -0.40M | -0.06M |
| Common stock total equity | - | - | - | 0.03M | - |
| Retained earnings total equity | - | - | - | -522.20M | - |
| Non currrent assets other | 53.08M | 50.21M | 45.04M | 22.25M | 16.05M |
| Non current assets total | 317.28M | 285.63M | 202.33M | 159.45M | 157.44M |
| Capital lease obligations | 81.68M | 90.47M | 94.87M | 96.10M | 96.35M |
| Long term debt total | - | - | - | 34.94M | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -230.71M | -122.98M | -10.72M | -22.60M | 133.33M |
| Change to liabilities | - | - | - | 11.48M | 8.25M |
| Total cashflows from investing activities | -277.06M | -122.98M | -1.21M | -52.43M | 105.26M |
| Net borrowings | 0.00M | 619.84M | 0.00M | 13.53M | -11.67M |
| Total cash from financing activities | 12.61M | 511.38M | 8.82M | 26.72M | -28.58M |
| Change to operating activities | - | - | - | 4.43M | 4.05M |
| Net income | -44.55M | -113.29M | -123.41M | -116.16M | -101.36M |
| Change in cash | -183.59M | 391.78M | -42.66M | -48.73M | 38.93M |
| Begin period cash flow | 419.60M | 36.17M | 78.83M | 127.56M | 88.63M |
| End period cash flow | 236.01M | 427.95M | 36.17M | 78.83M | 127.56M |
| Total cash from operating activities | 80.86M | 3.39M | -50.10M | -23.01M | -37.75M |
| Issuance of capital stock | - | - | - | 0.00M | 0.00M |
| Depreciation | 26.48M | 25.78M | 22.14M | 19.61M | 9.84M |
| Other cashflows from investing activities | -277.06M | -15.00M | - | - | - |
| Change to inventory | -8.51M | -0.22M | 0.98M | -5.11M | -4.96M |
| Change to account receivables | -95.43M | -91.92M | -81.19M | -61.84M | -53.57M |
| Sale purchase of stock | 0.00M | -25.00M | 0.00M | 13.18M | - |
| Other cashflows from financing activities | 12.61M | -91.93M | 8.82M | 34.92M | -222.94M |
| Change to netincome | - | - | - | 81.17M | 99.99M |
| Capital expenditures | 46.34M | 48.94M | 40.42M | 29.83M | 28.07M |
| Change receivables | - | - | - | -61.84M | - |
| Cash flows other operating | - | - | - | 54.51M | - |
| Cash and cash equivalents changes | - | - | - | -48.73M | - |
| Change in working capital | -91.70M | -99.12M | -102.05M | -65.51M | -46.23M |
| Stock based compensation | 88.28M | 75.98M | 77.20M | 57.74M | 54.53M |
| Other non cash items | 102.35M | 114.04M | 76.00M | 81.30M | 6.75M |
| Free cash flow | 34.52M | -45.55M | -90.53M | -52.84M | -65.82M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| IRTC iRhythm Technologies Inc |
-3.43 2.68% |
124.37 | - | 91.74 | 4.47 | 19.83 | 4.69 | 144.24 |
| ABT Abbott Laboratories |
1.38 1.32% |
105.95 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| MDT Medtronic PLC |
-0.32 0.33% |
96.79 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| SYK Stryker Corporation |
-19.22 6.17% |
292.53 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 | 17.16 |
| SEMHF Siemens Healthineers AG |
-0.11 0.22% |
47.69 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days; Zio XT System, a prescription-only remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and Zio ECG Utilization Software System, which supports the capture and analysis of ECG data. In addition, the company offers Zio AT System, a prescription-only remote ECG monitoring system, which consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days, as well as incorporates the Zio AT wireless gateway to provide connectivity between the patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with BioIS to develop and commercialize pulse oximetry, accelerometry, and trending non-invasive blood pressure technologies for use within ambulatory cardiac monitoring products and services. The company was formerly known as iRhythm Technologies, Inc. and changed its name to iRhythm Holdings, Inc. in January 2026. iRhythm Holdings, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
699 8th Street, San Francisco, CA, United States, 94103
415 632 5700
2400
| Name | Title | Year Born |
|---|---|---|
| Mr. Quentin S. Blackford | Pres, CEO & Director | 1979 |
| Mr. Douglas J. Devine | COO & Sec. | 1970 |
| Mr. Mark J. Day Ph.D. | Chief Technology Officer | 1971 |
| Mr. David A. Vort | Strategic Advisor | 1966 |
| Mr. Daniel G. Wilson | Exec. VP of Corp. Strategy | 1982 |
| Mr. Brice Bobzien CPA | Chief Financial Officer | NA |
| Dr. Mintu P. Turakhia M.D. | Chief Medical Officer & Chief Scientific Officer | NA |
| Mr. Patrick Michael Murphy J.D. | Chief Legal Officer | 1979 |
| Ms. Reyna M. Fernandez | Exec. VP & Chief HR Officer | 1967 |
| Mr. Mazi Kiani | Sr. VP of Quality & Regulatory | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-2.00%
Communication Services
-0.40%
Consumer Cyclical
-0.24%
Consumer Defensive
+0.34%
Energy
-0.17%
Financial Services
-0.79%
Financials
+2.35%
Healthcare
-1.57%
Industrials
-1.05%
Real Estate
-0.31%
Technology
-3.26%
Utilities
-0.30%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...